Revelation Biosciences, Inc. (REVB) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.
Analysts estimate Earnings Per Share (EPS) of $-1,436.16 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-9.44 vs est $-1,436.16 (beat +99.3%). 2025: actual $-23.95 vs est $-36.60 (beat +34.6%). Analyst accuracy: 0%.
REVB Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Revelation Biosciences, Inc. in the past 3 months
EPS Estimates — REVB
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$9.44
vs Est –$1,436.16
▲ 15,113.6% off
2025
Actual –$23.95
vs Est –$36.60
▲ 52.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — REVB
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
